A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression

Trial Profile

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression

Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2018

At a glance

  • Drugs ADCT 502 (Primary)
  • Indications Bladder cancer; Breast cancer; Cholangiocarcinoma; Gastric cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors ADC Therapeutics
  • Most Recent Events

    • 25 Apr 2018 According to an ADC Therapeutics media release, the company is collecting and evaluating the study data from the ADCT-502 Phase I trial, which will be presented for publication later this year.
    • 20 Apr 2018 Status changed from recruiting to discontinued due to safety.
    • 19 May 2017 According to an ADC Therapeutics media release, the first patient has been dosed in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top